Dayenne Giovanna van Leeuwen
| Title | Graduate Student |
|---|
| Institution | Baylor College of Medicine |
|---|
| Department | Immunology & Microbiology |
|---|
| Address | |
|---|
| vCard | Download vCard |
|---|
|
|
|
Bibliographic
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media.
(Note that publications are often cited in additional ways that are not shown here.)
Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication.
Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication.
Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.)
Click a Field or Translation tag to filter the publications.
-
Ma R, Woods M, Burkhardt P, Crooks N, van Leeuwen DG, Shmidt D, Couturier J, Chaumette A, Popat D, Hill LC, Rouce RH, Thakkar S, Orozco AF, Carisey AF, Brenner MK, Mamonkin M. Chimeric antigen receptor-induced antigen loss protects CD5.CART cells from fratricide without compromising on-target cytotoxicity. Cell Rep Med. 2024 Jul 16; 5(7):101628.
PMID: 38986621; PMCID: PMC11293353.
Citations:
1 Fields:
Translation:
HumansAnimalsCells
-
Watanabe N, Mo F, Zheng R, Ma R, Bray VC, van Leeuwen DG, Sritabal-Ramirez J, Hu H, Wang S, Mehta B, Srinivasan M, Scherer LD, Zhang H, Thakkar SG, Hill LC, Heslop HE, Cheng C, Brenner MK, Mamonkin M. Feasibility and preclinical efficacy of CD7-unedited CD7 CAR T?cells for T?cell malignancies. Mol Ther. 2023 01 04; 31(1):24-34.
PMID: 36086817; PMCID: PMC9840107.
Citations:
-
Geyer MB, Wang X, Wang Y, Purdon TJ, Hsu M, Devlin SM, Palomba ML, Halton E, Bernal Y, van Leeuwen DG, Sadelain M, Park JH, Brentjens RJ, Rivi?re I, S?n?chal B. Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL. JCI Insight. 2019 04 02; 5.
PMID: 30938714; PMCID: PMC6538317.
Citations:
25 Fields:
Translation:
HumansCTClinical Trials
-
Kuhn NF, Purdon TJ, van Leeuwen DG, Lopez AV, Curran KJ, Daniyan AF, Brentjens RJ. CD40 Ligand-Modified Chimeric Antigen Receptor T Cells Enhance Antitumor Function by Eliciting an Endogenous Antitumor Response. Cancer Cell. 2019 03 18; 35(3):473-488.e6.
PMID: 30889381; PMCID: PMC6428219.
Citations:
71 Fields:
Translation:
HumansAnimalsCells
-
Rafiq S, Yeku OO, Jackson HJ, Purdon TJ, van Leeuwen DG, Drakes DJ, Song M, Miele MM, Li Z, Wang P, Yan S, Xiang J, Ma X, Seshan VE, Hendrickson RC, Liu C, Brentjens RJ. Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. Nat Biotechnol. 2018 10; 36(9):847-856.
PMID: 30102295; PMCID: PMC6126939.
Citations:
223 Fields:
Translation:
HumansAnimalsCells
-
Avanzi MP, Yeku O, Li X, Wijewarnasuriya DP, van Leeuwen DG, Cheung K, Park H, Purdon TJ, Daniyan AF, Spitzer MH, Brentjens RJ. Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System. Cell Rep. 2018 05 15; 23(7):2130-2141.
PMID: 29768210; PMCID: PMC5986286.
Citations:
101 Fields:
Translation:
HumansAnimalsCells
-
Curran KJ, Seinstra BA, Nikhamin Y, Yeh R, Usachenko Y, van Leeuwen DG, Purdon T, Pegram HJ, Brentjens RJ. Enhancing antitumor efficacy of chimeric antigen receptor T cells through constitutive CD40L expression. Mol Ther. 2015 Apr; 23(4):769-78.
PMID: 25582824; PMCID: PMC4395796.
Citations:
101 Fields:
Translation:
HumansAnimalsCells
-
Pegram HJ, Purdon TJ, van Leeuwen DG, Curran KJ, Giralt SA, Barker JN, Brentjens RJ. IL-12-secreting CD19-targeted cord blood-derived T cells for the immunotherapy of B-cell acute lymphoblastic leukemia. Leukemia. 2015 Feb; 29(2):415-22.
PMID: 25005243; PMCID: PMC5189717.
Citations:
This graph shows the total number of publications by year. To see the data as text,
click here.
This graph shows the total number of publications by year. To return to the graph,
click here.
| Year | Publications |
|---|
| 2014 | 1 |
| 2015 | 1 |
| 2018 | 2 |
| 2019 | 2 |
| 2022 | 1 |
| 2024 | 1 |
This graph shows the number and percent of publications by field.
Fields are based on how the National Library of Medicine (NLM) classifies the publications' journals and might not represent the specific topics of the publications.
Note that an individual publication can be assigned to more than one field. As a result, the publication counts in this graph might add up to more than the number of publications the person has written.
To see the data as text,
click here.
This graph shows the number and percent of publications by field.
Fields are based on how the National Library of Medicine (NLM) classifies the publications' journals and might not represent the specific topics of the publications.
Note that an individual publication can be assigned to more than one field. As a result, the publication counts in this graph might add up to more than the number of publications the person has written.
To see the data as text,
click here.
newest
oldest
line numbers
double spacing
all authors
publication IDs